Sacituzumab Govitecan as a Treatment Option for Patients with metastatic triple-negative Breast Cancer and impending Liver Failure: two Case Reports

被引：0
|
作者：
Wolf, E. E. [1 ]
Agabejli, S. [1 ]
Wimberger, P. [1 ]
Link, T. [1 ]
机构：
[1] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Inst Abt Gynakol & Geburtshilfe, Dresden, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2023年 / 83卷 / 06期
关键词：
D O I：
10.1055/s-0043-1769875
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
66
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [1] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [2] Sacituzumab Govitecan for treating Patients with metastatic triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (12) : 1271 - 1271
  • [3] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [4] Sacituzumab govitecan in triple-negative breast cancer
    de Nonneville, Alexandre
    Goncalves, Anthony
    Mamessier, Emilie
    Bertucci, Francois
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [5] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [6] New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 723 - 725
  • [7] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 741 - 751
  • [8] Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
    Chen, Jigang
    Han, Mingyang
    Liu, Aihua
    Shi, Bo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
    Ozaki, Yukinori
    Masuda, Jun
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2382 - 2382
  • [10] Sacituzumab govitecan-hziy for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (04): : E194 - E194
12345